Therefore, OspC C7 may be a viable candidate for a human Lyme disease vaccine These studies indicate that including OspC in a comprehensive Lyme disease vaccine may be vital. Vaccination with OspC ...

the bacterium that causes Lyme disease. The vaccine blocks the protein, OspA, which prevents the spiral-shaped bacterium from being able to leave the tick and infect any humans it has bitten ...

Linden Hu, a professor of immunology specializing in Lyme disease at Tufts University, explains why creating a good Lyme vaccine is so ... A), but when it enters humans, OspA shuts off and the ...

It’s in those days of quiet blood-thirst that ticks pass along bacteria that causes conditions like Lyme disease ... the tiny tick is able to evade the human body’s defenses and pass along ...

With this success and seeing that mice and human immune cells react similarly ... several applications for their patented vaccine strategy against Lyme disease. This may include working with ...

The clinical trial for the potential vaccine, VLA15, began in August 2022. Stage 3 trials got underway in late 2023, ...

There are currently no approved human vaccines for Lyme disease, and VLA15 is the Lyme disease vaccine candidate which has advanced the furthest along the clinical development timeline ...

It wouldn’t be the first time a Lyme disease vaccine went to market ... California-based company Tarsus announced a successful Phase 2 human trial for a tick-killing medication.

Linden Hu, a professor of immunology specializing in Lyme disease at Tufts University, explains why creating a good Lyme vaccine is so ... A), but when it enters humans, OspA shuts off and the ...

Linden Hu, a professor of immunology specializing in Lyme disease at Tufts University, explains why creating a good Lyme vaccine is so ... A), but when it enters humans, OspA shuts off and the ...